Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond — Credit Rating and Financial Key Figures

Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR number: 30197372) is a company from KØBENHAVN. The company recorded a gross profit of 7031.6 kDKK in 2024. The operating profit was 385.8 kDKK, while net earnings were 1408.7 kDKK. The profitability of the company measured by Return on Assets (ROA) was 5.5 %, which can be considered decent but Return on Equity (ROE) was 31.1 %, which can be considered excellent. The equity ratio, a key indicator for solidity, stood at 19.8 %, a level that can be considered to be very low. This means the company is highly leveraged, with most assets financed through debt. This high level of financial risk could pose challenges in periods of financial distress or rising interest rates. Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond's liquidity measured by quick ratio was 1.5 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.